FDA Panel Says Birth Control Patch Should Stay on Market

Women, be careful out there.
http://www.medpagetoday.com/PublicHealthPolicy/PublicHealth/30133
An FDA advisory panel has voted 19-5 that the benefits of the Ortho Evra norelgestromin/ethinyl estradiol transdermal patch outweigh potential blood clot risks, but panel members think those risks should be more clearly stated on the label.